Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Sep;27(3):182-188.
doi: 10.1111/jns.12502. Epub 2022 May 29.

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands

Merel C Broers  1 , Marcel de Wilde  2 , Hester F Lingsma  3 , Johan van der Lei  2 , Katia M C Verhamme  2   4   5 , Bart C Jacobs  1   6
Affiliations
Case Reports

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands

Merel C Broers et al. J Peripher Nerv Syst. 2022 Sep.

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare but disabling disorder that often requires long-term immunomodulatory treatment. Background incidence rates and prevalence and risk factors for developing CIDP are still poorly defined. In the current study, we used a longitudinal population-based cohort study in The Netherlands to assess these rates and demographic factors and comorbidity associated with CIDP. We determined the incidence rate and prevalence of CIDP between 2008 and 2017 and the occurrence of potential risk factors in a retrospective Dutch cohort study using the Integrated Primary Care Information (IPCI) database. Cases were defined as CIDP if the diagnosis of CIDP was described in the electronic medical file. In a source population of 928 030 persons with a contributing follow-up of 3 525 686 person-years, we identified 65 patients diagnosed with CIDP. The overall incidence rate was 0.68 per 100 000 person-years (95% CI 0.45-0.99). The overall prevalence was 7.00 per 100 000 individuals (95% CI 5.41-8.93). The overall incidence rate was higher in men compared to woman (IRR 3.00, 95% CI 1.27-7.11), and higher in elderly of 50 years or older compared with people <50 years of age (IRR 17 95% CI 4-73). Twenty percent of CIDP cases had DM and 9% a co-existing other auto-immune disease. These background rates are important to monitor changes in the frequency of CIDP following infectious disease outbreaks, identify potential risk factors, and to estimate the social and economic burden of CIDP.

Keywords: CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; epidemiology; incidence; prevalence.

PubMed Disclaimer

Conflict of interest statement

M.C. Broers and H.F. Lingsma report grants from Dutch Prinses Beatrix Spierfonds, during the conduct of the study. M. de Wilde, J. van der Lei and K. Verhamme work for a research institute who receives/received unconditional research grants from Yamanouchi, Pfizer‐Boehringer Ingelheim, GSK, Amgen, UCB, Novartis, Astra‐Zeneca, Chiesi, Janssen Research and Development, none of which relate to the content of this work. B.C. Jacobs reports grants from Dutch Prinses Beatrix Spierfonds during the conduct of the study; grants from Dutch Prinses Beatrix Spierfonds, Horizon 2020, GBS‐CIDP Foundation International, Baxalta, Grifols, CSL Behring, Annexon and Hansa Biopharma, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Identification of cases with CIDP from the total study population. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy, IPCI, Integrated Primary Care Information database. aSelection of software systems containing sufficient discharge letters
See this image and copyright information in PMC

References

    1. Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;2017(1):CD010369. - PMC - PubMed
    1. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46. - PubMed
    1. Bunschoten C, Blomkwist‐Markens PH, Horemans A, van Doorn PA, Jacobs BC. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):253‐259. - PubMed
    1. Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis. Neuroepidemiology. 2019;52(3–4):161‐172. - PMC - PubMed
    1. Doneddu PE, Bianchi E, Cocito D, et al. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Antecedent events, lifestyle and dietary habits. Data from the Italian CIDP satabase. Eur J Neurol. 2020;27(1):136‐143. - PubMed

Publication types